7Baggers
 stocknews.com begins coverage on medicinova (nasdaq:mnov)  富途牛牛 Wed, 24 Sep 2025 23:37:44 GMT
 MediciNova concludes subject enrolment in trial of MN-166  Yahoo Finance Tue, 23 Sep 2025 07:00:00 GMT
 medicinova (mnov) maintains "buy" rating from d. boral capital |  GuruFocus Mon, 22 Sep 2025 14:38:58 GMT
 MediciNova completes patient enrollment in phase 2/3 ALS trial  Investing.com Mon, 22 Sep 2025 13:34:34 GMT
 MediciNova (MNOV) Completes Enrollment for Key ALS Treatment Tri  GuruFocus Mon, 22 Sep 2025 12:53:32 GMT
 MediciNova (NASDAQ:MNOV) Upgraded at Zacks Research  Defense World Sun, 14 Sep 2025 06:05:47 GMT
 published on: 2025-09-08 17:37:56  beatles.ru Mon, 08 Sep 2025 14:38:30 GMT
 MediciNova Provides Shareholder Update on Key Developments  GlobeNewswire Mon, 08 Sep 2025 07:00:00 GMT
 medicinova provides update on sepa, combat-als trial enrollment  TipRanks Mon, 08 Sep 2025 07:00:00 GMT
 medicinova secures $30 million equity purchase agreement as als trial hits target  Investing.com Canada Mon, 08 Sep 2025 07:00:00 GMT

MediciNova, Inc
(NASDAQ:MNOV) 

MNOV stock logo

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treati...

Founded: 2000
Full Time Employees: 8
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends